|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.94 USD | -2.40% |
|
-13.23% | -12.15% |
| 08/05 | Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says | MT |
| 07/05 | Sarepta Therapeutics, Inc., Q1 2026 Earnings Call, May 06, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5d. change | Varia. Jan 1. | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SAREPTA THERAPEUTICS, INC. | Diagnostic & Testing Substances Manufacturers | -2.58% | -13.23% | -12.15% | -48.02% | -74.41% | 204.82Cr |  |  | |
- Stock Market
- Equities
- SRPT Stock
- Charts Sarepta Therapeutics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition